

This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

# ALSTON&BIRD LLP

RECEIVED

3201 Beechleaf Court, Suite 600  
Raleigh, NC 27604-1062  
Tel: 919-862-2200  
Fax: 919-862-2260

5 DEC 2007

Legal Staff  
International Division

## TELECOPY

PLEASE DELIVER AS SOON AS POSSIBLE

December 5, 2007

Date:

Recipient:

PCT Legal Office

Fax Number:

(571) 273-0459

Sender:

Leslie T. Henry

Message:

Application No.:

10/576,943

Confirmation No. 1890

Filed:

December 1, 2006

Group Art Unit: 1641

For:


USE OF ANTAGONIST ANTI-CD40 ANTIBODIES FOR TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES

Pursuant to our telephone inquiry of this morning, as requested, we are faxing our request for a corrected filing receipt that was previously filed via EFS Web on 8/31/07. Please find attached:

- 1) Filing Receipt Dated 9/21/07 (3 pages)
- 2) Request for Corrected Filing Receipt and supporting documents originally filed on 8/31/07 via EFS Web Filing (7 pages)
- 3) Electronic Acknowledgement Receipt dated 8/31/07 (2 pages)
- 4) Clean copy of original Filing Receipt dated 8/24/07 (3 pages)

Specifically, in the section "Domestic priority data as claimed by the applicant," in lines 3 and 4 of the domestic priority data, an asterisk (\*) appears immediately following the filing dates 11/26/03 (line 3) and 4/27/04 (line 4) with a further comment provided on line 5 stating "Data provided by applicant is not consistent with PTO Records." However, Applicants submit that this priority data is correct in view of the attached supporting documents and respectfully request a corrected filing receipt reflecting the deletion of the asterisk (\*) and accompanying comment.

Respectfully submitted



Leslie T. Henry (45,714)

Tel: (919) 862-2229

Number of Pages: (including cover page) 16

IF NOT RECEIVED PROPERLY, PLEASE NOTIFY US IMMEDIATELY AT 862-2221.

USER CODE:	GRAVD	REQUESTED BY:	Dianne Gravius
CLIENT/MATTER:	035784/309941	OPERATOR:	



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Admistrative Conference for Patents  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NUMBER	FILING OR 371(C) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
10/576,943	12/01/2006	1641	1680	035784/309941	19	5

CONFIRMATION NO. 1890

826

ALSTON & BIRD LLP  
 BANK OF AMERICA PLAZA  
 101 SOUTH TRYON STREET, SUITE 4000  
 CHARLOTTE, NC28280-4000

## FILING RECEIPT

Date Mailed: 09/21/2007

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

## Applicant(s)

Li Long, Emeryville, CA;  
 Mohammad Luqman, Danville, CA;  
 Asha Yabannavar, Lafayette, CA;  
 Isabel Zaror, Emeryville, CA;

## Assignment For Published Patent Application

Chiron Corporation, Emeryville, CA

Power of Attorney: The patent practitioners associated with Customer Number 00826

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US04/36957 11/04/2004  
 which claims benefit of 60/517,337 11/04/2003

and claims benefit of 60/525,579 11/26/2003.

and claims benefit of 60/565,710 04/27/2004.

(\*Data provided by applicant is not consistent with PTO records.

## Foreign Applications

If Required, Foreign Filing License Granted: 08/22/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is  
**US10/576,943**

Projected Publication Date: 12/27/2007

**Non-Publication Request: No**

**Early Publication Request: No**

**Title**

Use of Antagonist Anti-CD40 Antibodies for Treatment of Autoimmune and Inflammatory Diseases and Organ Transplant Rejection

**Preliminary Class**

424

**PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES**

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timelines and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

**LICENSE FOR FOREIGN FILING UNDER**

**Title 35, United States Code, Section 184**

**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to

revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, or other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form, Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

Attorney's Docket No. 035784/309941

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

In re: Long *et al.* Confirmation No.: 1890  
Appl. No.: 10/576,943 Group Art Unit: 1636  
Filed: December 1, 2006  
For: USE OF ANTAGONIST ANTI-CD40 ANTIBODIES FOR TREATMENT OF  
AUTOIMMUNE AND INFLAMMATORY DISEASES

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REQUEST FOR CORRECTED FILING RECEIPT**

Sir:

In reviewing the Filing Receipt for the above-referenced application, Applicants note that errors appear as noted on the enclosed copy of the Filing Receipt. Specifically:

- 1) the second inventor's last name "Lugman" should read as -- Luqman --; and
- 2) in the title, "Anti-Cd40" should read as -- Anti-CD40 --.

Further, in the section entitled "Domestic Priority data as claimed by applicant," in lines 3 and 4 of the recorded priority data, an asterisk (\*) appears immediately following the filing dates 11/26/2003 (line 3) and 04/27/2004 (line 4), with a further comment provided on line 5, stating "(\*) Data provided by applicant is not consistent with PTO records." However, Applicants respectfully submit that this priority data is correct in view of the following documents attached hereto:


(A) a copy of the PCT Notification Concerning Submission or Transmittal of Priority Document for corresponding PCT/US04/036957, acknowledging receipt from the U.S. Patent and Trademark Office of the U.S. priority documents having the identical Application Nos. and filing dates as listed on lines 3 and 4 of the priority data recorded on the official Filing Receipt;

- (B) a copy of page 2 of the Declaration by the inventors for the above-referenced application, filed with the Response to Notification of Missing Requirements on December 1, 2006, showing the inventors' claim for priority to the identical Application Nos. and filing dates as listed on lines 3 and 4 of the priority data recorded on the official Filing Receipt; and
- (C) a copy of page 4 of the Application Data Sheet for the above-referenced application, filed at national-phase entry on April 21, 2006, showing a claim for priority to the identical Application Nos. and filing dates as listed on lines 3 and 4 of the priority data recorded on the official Filing Receipt.

Accordingly, Applicants respectfully submit that the data provided by Applicants is consistent with the PTO records. Should the Patent Office disagree, Applicants respectfully request clarification as to what data within these two lines is not consistent with PTO records.

In summary, Applicants request that a Corrected Filing Receipt addressing the errors in items 1) and 2) above be issued, and that the Corrected Filing Receipt reflect the deletion of the asterisk (\*) immediately following the filing dates listed on lines 3 and 4 of the priority data and the deletion of the comment "(\*) Data provided by applicant is not consistent with PTO records."

Respectfully submitted,

  
Leslie T. Henry  
Registration No. 45,714

Customer No. 00826  
ALSTON & BIRD LLP  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Raleigh Office (919) 862-2200  
Fax Raleigh Office (919) 862-2260

LEGAL02/30508310v1



## UNITED STATES PATENT AND TRADEMARK OFFICE

ALSTON &amp; BIRD LLP

 UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 GOVERNMENT AGENCY FOR PATENTS  
 1500 Pennsylvania Avenue, N.W.  
 Washington, D.C. 20591-1000  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov


AUG 27 2007

APPL. NO.	FILING OR 371(c) DATE	ART UNIT	FIL. FEE REC'D	RECEIVED BY CLERK/DOCKET NO.	TOT CLMS	IND CLMS
10/576,943	12/01/2006	1636	1680	035784/309941	19	5

826

ALSTON & BIRD LLP  
 BANK OF AMERICA PLAZA  
 101 SOUTH TRYON STREET, SUITE 4000  
 CHARLOTTE, NC 28280-4000

## FILING RECEIPT



OC000000025607731\*

CONFIRMATION NO. 1890

Receipt is acknowledged of this nonprovisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s):

Li Long, Emeryville, CA;  
 Mohammad Lugman, Danville, CA; *Lugman*  
 Asha Yabannaver, Lafayette, CA;  
 Isabel Zaror, Emeryville, CA;

**Power of Attorney:** The patent practitioners associated with Customer Number 00826.

## Domestic Priority data as claimed by applicant


This application is a 371 of PCT/US04/36957 11/04/2004  
 which claims benefit of 60/517,337 11/04/2003  
 and claims benefit of 60/525,579 11/26/2003 \* *←*  
 and claims benefit of 60/565,710 04/27/2004 \* *←*  
 (\*)Data provided by applicant is not consistent with PTO records. *←*

## Foreign Applications

**If Required, Foreign Filing License Granted:** 08/22/2007

**The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/576,943**

**Projected Publication Date:** 11/29/2007



Non-Publication Request: No

Early Publication Request: No

**Title**

CD40  
Use of Antagonist Anti-CD40 Antibodies for Treatment of Autoimmune and Inflammatory Diseases and Organ Transplant Rejection

**Preliminary Class**

435

**PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES**

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing-of-an-international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where

## PATENT COOPERATION TREATY

PCT/US04/036957

## PCT

NOTIFICATION CONCERNING  
SUBMISSION OR TRANSMITTAL  
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

From the INTERNATIONAL BUREAU

To:

ALEXANDER, Lisa, E.  
 Chiron Corporation  
 Intellectual Property Department  
 P.O. Box 8097  
 Emeryville, CA 94662-8097  
 ETATS-UNIS D'AMERIQUE

COPY

Date of mailing (day/month/year) 03 March 2005 (03.03.2005)
----------------------------------------------------------------

Applicant's or agent's file reference  
PP23725.001

## IMPORTANT NOTIFICATION

International application No.  
PCT/US04/036957International filing date (day/month/year)  
04 November 2004 (04.11.2004)

International publication date (day/month/year)

Priority date (day/month/year)  
04 November 2003 (04.11.2003)

Applicant

CHIRON CORPORATION et al.

1. By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
2. (If applicable) The letters "NR" appearing in the right-hand column denote a priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
3. (If applicable) An asterisk (\*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b) (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as the priority document, Rule 17.1(c) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

Priority date	Priority application No.	Country or regional Office or PCT receiving Office	Date of receipt of priority document
04 November 2003 (04.11.2003)	60/517,337	US	02 February 2005 (02.02.2005)
26 November 2003 (26.11.2003)	60/525,579	US	02 February 2005 (02.02.2005)
27 April 2004 (27.04.2004)	60/565,710	US	02 February 2005 (02.02.2005)

The International Bureau of WIPO  
 34, chemin des Colombettes  
 1211 Geneva 20, Switzerland

Facsimile No. +41 22 740 14 35

Authorized officer

Bellour Veronique

Facsimile No. +41 22 338 87 40  
 Telephone No. +41 22 338 8602

(B)

PATENT  
Atty. Docket No. 23725.0002

COPY

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
		<u>Patented, Pending, Abandoned</u>
60/517,337	4 November 2003	Abandoned
60/525,579	26 November 2003	Abandoned
60/565,710	27 April 2004	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor Li LongInventor's signature YR (Yann) Date 7/15/06Residence 124 Jade ct, Hercules, CA 94547Citizenship CanadaPost Office Address 4560 Horton Street, Emeryville, California 94608Full name of second inventor Mohammad LuqmanInventor's signature ML Date July 05, 06Residence Danville, CACitizenship USAPost Office Address 4560 Horton Street, Emeryville, California 94608

(C)

COPY

**Domestic Priority Information**

Application::	Continuity Type::	Parent Application::	Parent Filing Date::
This Application	National Stage of	PCT/US2004/036957	11/04/04

**Foreign Priority Information**

Country::	Application Number::	Filing Date::	Priority Claimed::
US	60/517,337	11/4/03	YES
US	60/525,579	11/26/03	YES
US	60/565,710	4/27/04	YES

**Assignee Information**

Assignee name:: Chiron Corporation  
Street of mailing address:: 4560 Horton Street  
City of mailing address:: Emeryville  
State or Province of mailing address:: CA  
Country of mailing address:: US  
Postal or Zip Code of mailing address:: 94608-2916

RTA01/2203821v1

## Electronic Acknowledgement Receipt

EFS ID:	2148990
Application Number:	10576943
International Application Number:	
Confirmation Number:	1890
Title of Invention:	Use of Antagonist Anti-Cd40 Antibodies for Treatment of Autoimmune and Inflammatory Diseases and Organ Transplant Rejection
First Named Inventor/Applicant Name:	Li Long
Customer Number:	826
Filer:	Ryan W. Cagle/Diann Gravius
Filer Authorized By:	Ryan W. Cagle
Attorney Docket Number:	035784/309941
Receipt Date:	31-AUG-2007
Filing Date:	01-DEC-2006
Time Stamp:	15:53:11
Application Type:	U.S. National Stage under 35 USC 371

## Payment Information:

Submitted with Payment	no
------------------------	----

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Corrected Filing Receipt	309941-RequestForCorrectedFilingReceipt.PDF	381087 6733464927#323500925738357309 7533469	no	7

Warnings:

**Information:**

Total Files Size (in bytes):	381087
------------------------------	--------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 1609 COAST GUARD PLAZA, SUITE 1450  
 RD Box 1450  
 Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
10/576,943	12/01/2006	1636	1680	035784/309941	19	5

## CONFIRMATION NO. 1890

826

ALSTON & BIRD LLP  
 BANK OF AMERICA PLAZA  
 101 SOUTH TRYON STREET, SUITE 4000  
 CHARLOTTE, NC28280-4000

## FILING RECEIPT

Date Mailed: 08/24/2007

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections.

## Applicant(s)

Li Long, Emeryville, CA;  
 Mohammad Lugman, Danville, CA;  
 Asha Yabannavar, Lafayette, CA;  
 Isabel Zaror, Emeryville, CA;

**Power of Attorney:** The patent practitioners associated with Customer Number 00826

**Domestic Priority data as claimed by applicant**

This application is a 371 of PCT/US04/36957 11/04/2004  
 which claims benefit of 60/517,337 11/04/2003  
 and claims benefit of 60/525,579 11/26/2003 \*  
 and claims benefit of 60/565,710 04/27/2004 \*

(\*Data provided by applicant is not consistent with PTO records.

## Foreign Applications

**If Required, Foreign Filing License Granted:** 08/22/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is  
**US10/576,943**

**Projected Publication Date:** 11/29/2007

**Non-Publication Request:** No

**Early Publication Request: No****Title**

Use of Antagonist Anti-Cd40 Antibodies for Treatment of Autoimmune and Inflammatory Diseases and Organ Transplant Rejection

**Preliminary Class**

435

**PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES**

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).